Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Arjun Narala, Dinesh Suram & Kishan Veerabrahma. (2021) Pharmacokinetic and pharmacodynamic studies of iloperidone-loaded lipid nanoemulsions via oral route of administration. Drug Development and Industrial Pharmacy 47:4, pages 618-625.
Read now
Read now
Fernanda S Tonin, Astrid Wiens, Fernando Fernandez-Llimos & Roberto Pontarolo. (2016) Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy. Core Evidence 11, pages 49-61.
Read now
Read now
Jeffrey T Rado & Philip G Janicak. (2014) Long-term efficacy and safety of iloperidone: an update. Neuropsychiatric Disease and Treatment 10, pages 409-415.
Read now
Read now
Navin V Dargani & Anil K Malhotra. (2014) Safety profile of iloperidone in the treatment of schizophrenia. Expert Opinion on Drug Safety 13:2, pages 241-246.
Read now
Read now
Leslie Citrome. (2011) Iloperidone, Asenapine, and Lurasidone: A Brief Overview of 3 New Second-Generation Antipsychotics. Postgraduate Medicine 123:2, pages 153-162.
Read now
Read now
Articles from other publishers (29)
Mujeeb U. Shad. (2023) Seventy Years of Antipsychotic Development: A Critical Review. Biomedicines 11:1, pages 130.
Crossref
Crossref
Jaime M. Monti, S. R. Pandi-Perumal, David Warren Spence & Pablo Torterolo. 2022. Sleep and Neuropsychiatric Disorders. Sleep and Neuropsychiatric Disorders
763
778
.
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Hong Joon Lee, Bok Hee Choi, Jin-Sung Choi & Sang June Hahn. (2021) Effects of iloperidone on hERG 1A/3.1 heterotetrameric channels. NeuroReport 32:16, pages 1299-1306.
Crossref
Crossref
Alexandre Vallée, Jean-Noël Vallée & Yves Lecarpentier. (2021) Lithium and Atypical Antipsychotics: The Possible WNT/β Pathway Target in Glaucoma. Biomedicines 9:5, pages 473.
Crossref
Crossref
Przemysław J. Danek, Jacek Wójcikowski & Władysława A. Daniel. (2020) The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions. Pharmacological Reports 72:6, pages 1685-1694.
Crossref
Crossref
Habibur Rahman, S.K. Manirul Haque & Masoom Raza Siddiqui. (2020) A Comprehensive Review on Importance and Quantitation of Atypical Antipsychotic Drugs and their Active Metabolites in Commercial Dosage Forms. Current Pharmaceutical Analysis 16:8, pages 989-1019.
Crossref
Crossref
Shrikant V. Joshi, Ekta P. Patel, Bhavin A. Vyas, Sandesh R. Lodha & Gajanan G. Kalyankar. (2020) Repurposing of Iloperidone: Antihypertensive and ocular hypotensive activity in animals. European Journal of Pharmaceutical Sciences 143, pages 105173.
Crossref
Crossref
Esther S. Lee, Hal Kronsberg & Robert L. Findling. (2020) Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children. Child and Adolescent Psychiatric Clinics of North America 29:1, pages 183-210.
Crossref
Crossref
Viswam Subeesh, Eswaran Maheswari, Hemendra Singh, Thomas Elsa Beulah & Ann Mary Swaroop. (2019) Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Current Drug Safety 14:1, pages 21-26.
Crossref
Crossref
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli & Alfredo Carlo Altamura. (2018) Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical Pharmacokinetics 57:12, pages 1493-1528.
Crossref
Crossref
Esther S. LeeCarol VidalRobert L. Findling. (2018) A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics. Journal of Child and Adolescent Psychopharmacology 28:9, pages 582-605.
Crossref
Crossref
Ruben Vardanyan. 2017. Piperidine-Based Drug Discovery. Piperidine-Based Drug Discovery
241
267
.
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
87
110
.
Leslie Citrome, Peter J. Weiden, Gus Alva, Ira D. Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng & Adam Winseck. (2015) Switching to Iloperidone. Clinical Schizophrenia & Related Psychoses 8:4, pages 183-195.
Crossref
Crossref
Lisette A. Rodriguez-Cabezas, Betty Y. Kong & Gaurava Agarwal. (2014) Priapism associated with iloperidone: a case report. General Hospital Psychiatry 36:4, pages 451.e5-451.e6.
Crossref
Crossref
Mark D Brennan. (2014) Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 15:6, pages 869-884.
Crossref
Crossref
J. Peuskens, L. Pani, J. Detraux & M. De Hert. (2014) The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. CNS Drugs.
Crossref
Crossref
Tingting Zhang, Yan Yang, Haitao Wang, Fuxing Sun, Xiaojun Zhao, Jiangtiao Jia, Jingrui Liu, Wei Guo, Xiaoqiang Cui, Jingkai Gu & Guangshan Zhu. (2013) Using Dissolution and Pharmacokinetics Studies of Crystal Form to Optimize the Original Iloperidone. Crystal Growth & Design 13:12, pages 5261-5266.
Crossref
Crossref
Leslie Citrome. (2013) A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach. CNS Drugs 27:11, pages 879-911.
Crossref
Crossref
Anja Cerovecki, Richard Musil, Ansgar Klimke, Florian Seemüller, Ekkehard Haen, Rebecca Schennach, Kai-Uwe Kühn, Hans-Peter Volz & Michael Riedel. (2013) Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations. CNS Drugs 27:7, pages 545-572.
Crossref
Crossref
Jignesh M Parekh, Mallika Sanyal, Manish Yadav & Pranav S Shrivastav. (2013) Stable-isotope dilution LC–MS/MS assay for determination of iloperidone and its two major metabolites, P 88 and P 95, in human plasma: application to a bioequivalence study. Bioanalysis 5:6, pages 669-686.
Crossref
Crossref
Nga Tran & Deirdre Alderton. 2012. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition. Pharmacological and Psychosocial Treatments in Schizophrenia, Third Edition
1
31
.
Marc De Hert, Weiping Yu, Johan Detraux, Kim Sweers, Ruud van Winkel & Christoph U. Correll. (2012) Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder. CNS Drugs 26:9, pages 733-759.
Crossref
Crossref
Patrick Vigneault, Sylvie Pilote, Dany Patoine, Chantale Simard & Benoit Drolet. (2012) Iloperidone (Fanapt®), a novel atypical antipsychotic, is a potent HERG blocker and delays cardiac ventricular repolarization at clinically relevant concentration. Pharmacological Research 66:1, pages 60-65.
Crossref
Crossref
David J. Castle, Nga Tran & Deirdre Alderton. 2012. Pharmacological and Psychosocial Treatments in Schizophrenia. Pharmacological and Psychosocial Treatments in Schizophrenia
1
31
.
Pierre Baumann & Christoph Hiemke. 2012. Metabolism of Drugs and Other Xenobiotics. Metabolism of Drugs and Other Xenobiotics
301
329
.
Mohammed Shahid. 2012. Designing Multi-Target Drugs. Designing Multi-Target Drugs
14
31
.
Peter Weiden. (2012) Iloperidone for the Treatment of Schizophrenia: An Updated Clinical Review. Clinical Schizophrenia & Related Psychoses 6:1, pages 34-44.
Crossref
Crossref